Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 16/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143316 | 0.81 | EPHX1 (0.55) | P2RX7AVPR1A | |
| SCHEMBL25464169 | 0.79 | LMNA (0.50) | P2RX7AVPR1A | |
| SCHEMBL31359373 | 0.78 | F10 (0.56) | CNR1TACR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13313619 | 0.77 | P2RX7 (0.40) | P2RX7AVPR1A | |
| SCHEMBL3135707 | 0.77 | P2RX7 (0.40) | P2RX7AVPR1A | |
| SCHEMBL3135713 | 0.77 | P2RX7 (0.40) | P2RX7AVPR1A | |
| SCHEMBL3135716 | 0.77 | P2RX7 (0.40) | P2RX7AVPR1A | |
| SCHEMBL13348709 | 0.75 | P2RX7 (0.39) | P2RX7AVPR1A | |
| SCHEMBL3144414 | 0.75 | PTGES (0.46) | P2RX7CNR1 | |
| SCHEMBL22169758 | 0.73 | CCR2 (0.44) | CNR1TAS1R3TAS1R1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD3B1 | P2RX7 3820/4885TRPV1 3619/4885CNR1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.